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After hematopoietic stem cell transplantation (HSCT), natural killer (NK) cell alloreactivity in HLA cells of
recipients is regulated by killer immunoglobulin-like receptors (KIRs) on donor NK cells. The effect of KIRs on
HSCT outcomes is controversial, particularly in those undergoing HLA-identical sibling HSCT. In this study,
effects of KIR and HLA genotypes on the HSCT outcome were investigated in a 5-year retrospective study
comprising 219 patient-donor pairs undergoing HLA-identical sibling HSCT for myeloid and lymphoid ma-
lignancies. We found that 39.7% (87 of 219) of these pairs, which were KIR mismatched, had better overall
survival (OS) and reduced grade III to IV acute graft-versus-host disease (aGVHD), especially in acute myeloid
leukemia (AML) patients. Bx1 donor KIR genotype with haplotype B on a telomeric region was a risk factor for
the OS and relapse-free survival (RFS). Donor centromeric (c) and telomeric (t) KIR haplotype analysis showed
that donor KIR cB-tA/tB was associated with improved OS and RFS compared with cA-tA or cA-tB. Further-
more, donor KIR B haplotype of the centromeric motifs (Cen-B) was an independent beneﬁcial factor in
improving OS and RFS and in protecting from relapse after HSCT. In AML patients, the occurrence of aGVHD
was signiﬁcantly lower in HLA-C1 group compared with that in HLA-C2 group, although such effect was not
observed in patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Our results
suggest that KIR could impact outcome and donor KIR haplotype with Cen-B confer signiﬁcant survival
beneﬁts to HLA-identical sibling HSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
HLA-identical hematopoietic stem cell transplantation
(HSCT) with siblings is a standard treatment for patients with
hematologic malignancies. In recent years, HSCT survival has
signiﬁcantly improved through advances in matching tech-
niques of HLA, along with better control of infections, graft-
versus-host disease (GVHD), and relapses. However, the
outcome is variable and dependent on several factors,
including disease stage, donor gender, age, cytomegalovirus
serostatus, degree of HLA identity between donor and
recipient, conditioning regimen, and GVHD [1].
Natural killer (NK) cells were discovered for their ability
to kill cancer cells and were later shown to be an essential
element of innate immunity [2]. Killer immunoglobulin-like
receptor (KIR) genes are expressed on NK cells and on sub-
sets of activated or memory T lymphocytes. In allogeneic
HSCT, donor NK cells attack the allogeneic cells if the recip-
ient HLA class I ligands do not sufﬁciently engage their
inhibitory receptors. Alloreactive donor-derived NK cells are
thought to promote engraftment [3-6], reduce GVHD [7,8],edgments on page 105.
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leukemic relapse [4,9,10], resulting in an antileukemic
response with lower relapse rates, fewer graft failures, and
less GVHD, ultimately leading to improved overall survival
(OS) [11,12]. Some recent studies have indicated that KIR
interactions of donor and recipient can inﬂuence the out-
comes of haploidentical [13-15], matched-unrelated donor
[3,16,17], and matched-related donor [2,5,18-22] allogeneic
HSCT, particularly in patients with acute myeloid leukemia
(AML).
Most studies have shown that donors carrying at least
one B haplotype had a better clinical outcome than those
receiving transplants from a donor homozygous for KIR
haplotype A, including a reduced risk of developing grade II
to IV acute GVHD [23] and a higher OS rate [15-17]. In
contrast, a previous study revealed the opposite result,
indicating that a donor-recipient pair in which the donor
has a group B KIR haplotype that is absent in the recipient
yields the poorest survival with increased relapse and acute
GVHD [2].
However, studies investigating KIR in large cohorts and
with a long follow-up for HLA-identical sibling HSCT are
lacking. In addition, much less information about Asian
and Chinese populations is available. To determine the in-
ﬂuence of donor KIR haplotype on the outcomes of HLA-
identical sibling HSCT in China, we performed KIR and
HLA genotyping of 219 donor and recipient pairs with
5-year follow-ups.Transplantation.
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Patients
The study population comprised 219 consecutive patients who visited
the First Afﬁliated Hospital of Soochow University betweenMarch 2005 and
October 2012. Patients with myeloid leukemia (acute myeloid leukemia
[AML], chronic myelogenous leukemia [CML], and myelodysplastic syn-
drome [MDS]) and lymphoid leukemia (acute lymphoblastic leukemia [ALL]
and non-Hodgkin lymphoma [NHL]) received HLA-identical sibling HSCT.
Transplantation risk was deﬁned as follows: AML, ALL, and NHL in ﬁrst
complete remission, CML in ﬁrst chronic phase, and MDS subtype refractory
anemiawere considered to be at standard risk. Others were considered to be
at high risk. The study protocol was approved by the First Afﬁliated Hospital
of SoochowUniversity Ethics Committee. All patients gavewritten informed
consent to their participation in the study, and the study followed the ethical
guidelines of the Declaration of Helsinki. End of follow-up was on January
31, 2013, and 6 patients were lost to follow-up. The median follow-up time
for survival patients was 24 months (3 to 93 months).
CONDITIONING REGIMEN AND GVHD PROPHYLAXIS
All patients received myeloablative conditioning. Most
patients received a conditioning regimen consisting of
cytarabine 2 g/m2 every 12 hours (on days 9 and 8),
busulfan 4 mg/kg every 6 hours (on days 7 to 5), and
cyclophosphamide 50 mg/(kg,day) (on days 4 to 3).
Patients with high risk of central nervous system leukemia
received a similar regimen, but with total body irradiation
(12 Gy, lung shielding at 8 Gy separated for 3 days, on
days 7 to 5) substituted for busulfan and cytarabine.
GVHD prophylaxis consisted of continuous cyclosporine A
infusion at 3 mg/(kg,day) starting on day 1 and short-
term methotrexate given on days þ1, þ3, þ6, and þ11 at
doses of 15, 10, 10, and 10 mg/m2, respectively. The onset
and grades of acute and chronic GVHD were assessed ac-
cording to published consensus criteria. Administration of
methylprednisolone 2 mg/(kg,day) constituted the ﬁrst-
line treatment for the development of grade  2 acute
GVHD.
HLA and KIR Genotyping
Peripheral blood samples were analyzed for HLA and
KIR genes. Genomic DNA was extracted using a Promega
DNA Extraction Kit (Promega, Madison, WI). Analyses of
HLA-A, -B, -C, -DRB1, and DQB1 genotypes were performed
using sequence-based typing, sequence-speciﬁc oligonu-
cleotide probemethods. Genotyping of KIR genes was per-
formed by PCR-SSP using SSP Kit (Invitrogen, Carlsbad, CA).
PCR ampliﬁcations were performed using a Perkin Elmer
GeneAmp 9700 thermal cycler (Perkin Elmer, Waltham,
MA).
The 3 original deﬁnitions of a KIR mismatch were: (1)
mismatch between the donor KIR and recipient KIR [24];
(2) mismatch between the donor KIR and recipient KIR
ligand [25]; and (3) mismatch between the donor KIR ligand
and recipient KIR ligand [4]. In our study, the ligand-ligand
mismatch was excluded because the donor and recipient
KIR ligands were exactly matched for HLA-identical sibling
HSCT. The potential KIR alloreactivity was assessed only by
the ﬁrst 2 types of KIR mismatches, which gave rise to 3 basic
models: gene-gene model, receptor-ligand model, and donor
haplotype model.
Donor and Recipient KIR Gene-gene Mismatch Model
A donor and recipient KIR gene match was deﬁned as the
donor and the recipient having the same KIR genotype. A
donor and recipient KIR gene mismatch was deﬁned as a KIR
gene that was present in the donor and absent in the recip-
ient or vice versa.Donor KIR Haplotype Model
Group A haplotype was deﬁned as a combination of 9
genes: KIR3DL3, 2DL3, 2DP1, 2DL1, 3DP1, 2DL4, 3DL1, 2DS4,
and 3DL2. Detection of at least 1 of the KIR B haplotype-
deﬁning loci (KIR2DL5, 2DS1, 2DS2, 2DS3, 2DS5, or 3DS1)
required that the genotype contains at least 1 group B
haplotype [26]. Individuals with only group A genes were
assigned as A/A genotype. Individuals with either 1 (A/B
heterozygous) or 2 (B/B homozygous) B haplotypes were
assigned the genotype as B/x genotype [27].
Further subdivision of the A haplotype into subgroups
resulted in designation of A-1 and A-2. A-1 was deﬁned as
haplotype A carrying full-length 2DS4, whereas A-2 was
deﬁned as haplotype A carrying deleted 1D variants. The
gene combinations of A-1 and A-2 can be divided into AA-1,
AA-2, and AA-3. For group B, there were 15 different haplo-
types named as B1 to B15 according to their frequencies. The
gene combinations of group A and B1/B2 haplotype were the
most frequent genotypes, named as Bx1 and Bx2 [26,27].
Donor Centromeric (Cen) and Telomeric (Tel) KIR
Haplotype Model
Genotypes for the Cen and Tel parts of the KIR locus were
assigned according to the presence or absence of 1 or more B
haplotype-deﬁning KIR genes. Cen-A01 (cA) contains the
gene combination of 3DL3, 2DL3, 2DP1, 2DL1, and 3DP1,
whereas Tel-A01 (tA) contains the gene combination of 2DL4,
3DL1, 2DS4, and 3DL2. A haplotype was composed of cA-tA.
Cen-B01 and Cen-B02 are alternative centromeric motifs of
common B KIR haplotypes that contain the gene combina-
tion of 3DL3, 2DS2, 2DL2, and 3DP1 (Cen-B01), or 3DL3, 2DS2,
2DL2, 2DL5B, 2DS3, 2DP1, 2DL1, and 3DP1 (Cen-B02) in the
centromeric region. Cen-B01 and Cen-B02 were shortened as
cB. The combination of 2DL4, 3DS1, 2DL5A, 2DS3/S5, 2DS1, and
3DL2 in the telomeric region was the most frequent haplo-
type B-speciﬁc telomeric segment and is deﬁned as Tel-B01
(tB) [26]. B haplotype could be composed of cB-tA, cB-tB,
and cA-tB (Figure 1. This ﬁgure was adopted from [26]).
Donor KIR Receptor and Recipient Ligand Mismatch
Model
Although the ligands for activating KIRs remain elusive,
the interactions between inhibitory KIRs and HLA class I
molecules determine NK-cell alloreactivity. KIR2DL2 and
KIR2DL3 recognize the HLA-C group 1 (C1)-related alleles
characterized by an asparagine residue at position 80 of the
a-1 helix (HLA-CAsn80), KIR2DL1 recognizes the HLA-C
group 2 (C2)-related alleles characterized by a lysine res-
idue at position 80 (HLA-CLys80), KIR3DL1 recognizes the
HLA-Bw4 alleles, and KIR3DL2 recognizes the HLA-A3/A11
alleles [5]. Patients were categorized according to their
HLA-inhibitory KIR ligand groups by determining whether
they expressed (1) HLA-A3 or -A11; (2) HLA-Bw4; or (3) HLA-
Cw groups (C1 or C2) [28].
Statistical Analysis
We considered the following outcomes for the statistical
analysis: OS, deﬁned as time from graft infusion to death
from any cause; relapse-free survival (RFS), deﬁned as the
time to relapse, censored at noncancer death; nonrelapse
mortality (NRM), deﬁned as the time to death from any cause
but relapse; aGVHD, deﬁned as development of grade II to IV
GVHD during the ﬁrst 100 days post-transplantation; and
chronic GVHD (cGVHD), deﬁned as GVHD at 100 days
Figure 1. KIR haplotype model and common haplotypes. The KIR locus comprises centromeric (Cen) and telomeric (Tel) gene content motifs.
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included in the cGVHD analysis (n ¼ 196).
The relationships between KIR and GVHD, relapse, and
NRM were tested using Fisher’s exact or chi-square tests;
multivariate proportional hazard regression models were
used to identify independent risk factors for aGVHD, cGVHD,
NRM, or relapse. OS and RFS were summarized by Kaplan-
Meier curves and compared using the log-rank test. All sta-
tistical tests were 2-sided, and a P value of < .05 was
considered statistically signiﬁcant. Cox proportional hazards
analysis was used to identify multivariable prognostic factors
for survival. Factors included patient age, gender match,
disease stage, type of conditioning, CD34þ stem cell dose,
graft type, ABO blood type, patient and donor KIR gene
compatibility, donor KIR haplotype, and KIR ligand compat-
ibility. Statistical analyses were performed in SPSS version
13.0 (SPSS Inc., Chicago, IL), and data graphs were drawn in
GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA).
RESULTS
Characteristics of the Transplant recipients and donors
Characteristics of the transplant recipients and donors are
summarized in Table 1. There was no difference between
matched and mismatched donor-recipient KIR pairs, donors
with and without Cen-B KIR haplotype, A3/A11þ and A3/
A11- HLA-A alleles recipients, Bw4 and Bw4- HLA-Bw alleles
recipients, and C1 and C2 HLA-C alleles recipients in age,
diagnosis of disease type, disease status, sex, graft type ABO
blood type, and conditioning regimen.
Impact on 5-year OS, RFS, and aGVHD
The 5-year percentages for OS and RFS were 76.2% and
69.6%, respectively. The percentages of OS for AML/MDS, ALL,
and CMLwere 72.7%, 67.9%, and 93.5% (P¼ .156), respectively,
and the percentages of RFS for AML/MDS, ALL, and CML were
68.7%, 73.3%, and 72.3% (P ¼ .239), respectively. The relapse
rate and transplantation-related mortality were 13.2% and
9.6%, respectively (data not shown).
The frequency of KIR gene distribution in the donors and
recipients was analyzed and no signiﬁcant difference was
found between recipient and donor (Figure 2).
HLA-identical sibling donor-recipient pairs showed KIR
mismatches of 39.7% (87 of 219), with 56.6% (124 of 219) of
donors having an A/A genotype and 34.4% (95 of 219) of
donors having B/x genotype. About 15.5% (34 of 219) of B/xgenotype donors had a centromeric B haplotype. KIR ligand
typing showed that 28.8% (63 of 219) of patients expressed
HLA-A3/A11 and 66.7% (146 of 219) of patients were Bw4
positive, of which 17.4% (38 of 219) were homozygous for
Bw4 and 49.3% (108 of 219) were heterozygous for Bw4/Bw6;
26.0% (57 of 219) had both C1/C2, 63.0% (138 of 219) were
homozygous for C1 alleles, and 11.0% (24 of 219) were ho-
mozygous for C2 alleles.Impact of Donor-recipient KIR Gene Mismatches on OS
and RFS after HLA-identical Sibling HSCT
Donor-recipient KIR genotype mismatches were associ-
ated with signiﬁcantly better 5-year OS (87.3% versus 69.3%;
hazard ratio [HR], 2.085; 95% conﬁdence interval [CI], 1.088
to 3.996; P ¼ .0268) (Figure 3A). The effect was apparent for
AML patients (88.3% versus 60.8%; HR, 2.38; 95% CI, 1.089 to
5.201; P ¼ .0297) (Figure 3B). However, the OS beneﬁt of KIR
gene mismatches was not found in patients with ALL (67.3%
versus 65.7%; HR,1.051; 95% CI, .2651 to 4.168; P¼ .9435) and
CML (100.0% versus 89.7; HR, 4.981; 95% CI, .2854 to 86.93;
P ¼ .2711). Analysis of RFS showed no signiﬁcant difference,
although a trend towards better survival was observed in the
donor-recipient KIR-mismatch group (77.0% versus 62.0%;
HR, 1.493; 95% CI, .8215 to 2.714; P ¼ .1885) (Figure 3C).
However, when only the 128 AML/MDS patients were
considered, RFS was improved in the donor-recipient KIR-
mismatch group (86.5% versus 59.9%; HR, 2.182; 95% CI,1.022
to 4.655; P ¼ .0437) (Figure 3D). There was no signiﬁcant
difference in NRM (P ¼ .075) or relapse (P ¼ .151) (data not
shown).
The patients with donor-recipient KIR mismatches had a
lower rate of grade III to IV aGVHD (4.6%) than those without
mismatches (13.6%; P ¼ .029); the lowest rate of grade III
to IV aGVHD was observed in the donor-recipient KIR-
mismatch group with a donor genotype of KIR B/x (2.0%),
whereas a KIR-match group with a donor genotype of KIR A/
A had the highest rate (12.9%; P ¼ .016). There was no sig-
niﬁcant difference in grade II to IV aGVHD (P ¼ .145) and
cGVHD (P ¼ .270). The relapse rate was higher in KIR-match
group, in which the donor had the KIR A/A genotype (18.4%),
than in a donor-recipient KIR-mismatch group, in which the
donor had the KIR B/x genotype (6.0%; P ¼ .043). These re-
sults highlighted that donor-recipient KIR genotype mis-
matches had a beneﬁcial effect on OS and RFS indicated by a
lower rate of grade III to IV aGVHD and relapse.
Table 1





P Donor KIR Haplotype P HLA-A Alleles of
Recipients
P HLA-Bw Alleles of
Recipients
P HLA-C Alleles of
Recipients
P




38 (8-63) 39 (8-62) 38 (12-63) .151 36 (13-63) 39 (8-62) .833 40 (13-60) 39 (8-63) .416 38 (8-62) 39.5 (8-63) .449 38 (8-63) 40 (8-62) .961
Diagnosis .512 .888 .106 .749
AML 111 (50.7) 65 (49.2) 46 (52.9) 15 (44.1) 96 (51.9) 27 (42.9) 84 (53.8) 78 (51.0) 33 (50.0) 68 (49.3) 43 (53.1) .747
MDS 17 (7.8) 8 (6.1) 9 (10.3) 3 (8.8) 14 (7.6) 2 (3.2) 15 (9.6) 13 (8.5) 4 (6.1) 11 (8.0) 6 (7.4)
ALL 40 (18.3) 28 (21.2) 12 (13.8) 7 (20.6) 33 (17.8) 13 (20.6) 27 (17.3) 25 (16.3) 15 (22.7) 25 (18.1) 15 (18.5)
CML 33 (15.1) 21 (15.9) 12 (13.8) 5 (14.7) 28 (15.1) 14 (22.2) 19 (12.2) 23 (15.0) 10 (15.2) 20 (14.5) 13 (16.0)
NHL 18 (8.2) 10 (7.6) 8 (9.2) 4 (11.8) 14 (7.6) 7 (11.1) 11 (7.1) 14 (9.2) 4 (6.1) 14 (10.1) 4 (4.9)
Disease status .627 .724 .507 .795 .051
Standard risk 160 (73.1) 98 (74.2) 62 (71.3) 24 (70.6) 136 (73.5) 48 (76.2) 112 (71.8) 111 (72.5) 49 (74.2) 107 (77.5) 53 (65.4)
High risk 59 (26.9) 34 (25.8) 25 (28.7) 10 (29.4) 49 (26.5) 15 (23.8) 44 (28.2) 42 (27.5) 17 (25.8) 31 (22.5) 28 (34.6)
Sex match,
donor/recipient
.623 .367 .828 .495 .296
Male/male 56 (25.6) 35 (26.5) 21 (24.1) 9 (26.5) 47 (25.4) 18 (28.6) 38 (24.4) 38 (24.8) 18 (27.3) 30 (21.7) 26 (32.1)
Male/female 55 (25.1) 29 (22.0) 26 (29.9) 12 (35.3) 43 (23.2) 17 (27.0) 38 (24.4) 35 (22.9) 20 (30.3) 34 (24.6) 21 (25.9)
Female/male 64 (29.2) 40 (30.3) 24 (27.6) 9 (26.5) 55 (29.7) 17 (27.0) 47 (30.1) 46 (30.1) 18 (27.3) 43 (31.2) 21 (25.9)
Female/female 44 (20.1) 28 (21.2) 16 (18.4) 4 (11.8) 40 (21.6) 11 (17.5) 33 (21.2) 34 (22.2) 10 (15.2) 31 (22.5) 13 (16.0)
Graft type .870 .382 .899 .695 .101
Peripheral blood
progenitor cells
82 (37.4) 50 (37.9) 32 (36.8) 15 (44.1) 67 (36.2) 24 (38.1) 58 (37.2) 56 (36.6) 26 (39.4) 46 (33.3) 36 (44.4)
Bone marrow 137 (62.6) 82 (62.1) 55 (63.2) 19 (55.9) 118 (63.8) 39 (61.9) 98 (62.8) 97 (63.4) 40 (60.6) 92 (66.7) 45 (55.6)
ABO blood type .552 .244 .677 .984 .889
Matched 123 (56.2) 72 (54.5) 51 (58.6) 16 (47.1) 107 (57.8) 34 (54.0) 89 (57.1) 86 (56.2) 37 (56.1) 78 (56.5) 45 (55.6)
Mismatched 96 (43.8) 60 (45.5) 36 (41.4) 18 (52.9) 78 (42.2) 29 (46.0) 67 (42.9) 67 (43.8) 29 (43.9) 60 (43.5) 36 (44.4)
Conditioning
regimen
BuCy 192 (87.7) 112 (84.8) 80 (92.0) .118 31 (91.2) 161 (87.0) .776 54 (85.7) 138 (88.5) .576 132 (86.3) 60 (90.9) .338 123 (89.1) 69 (85.2) .391




3.79 3.87 3.74 .483 4.07 3.79 .107 3.72 3.85 .226 3.73 4.09 .922 3.85 3.72 .777
(1.36-12.0) (1.70-12.0) (1.36-10.31) (1.84-10.31) (1.36-12.0) (1.36-9.38) (1.70-12.0) (1.36-12.0) (1.70-10.31) (1.84-12.0) (1.36-9.38)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkins lymphoma; TBI, total body irradiation; Bu, busulfan;
Cy, cyclophosphamide.
















Figure 2. Frequencies of 17 KIR genes for the donors and recipients. KIR genotyping was performed for both donors (n ¼ 219) and recipients (n ¼ 219), showing the
similar KIR gene frequencies.
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identical Sibling HSCT
All donors were assigned to 2 groups according to the KIR
genotypes A/A or B/x. No signiﬁcant differences in OS (72.1%
versus 80.4%; HR,1.455; 95% CI, .7706 to 2.747; P¼ .2476) and
RFS (52.4% versus 81.4%; HR, .6465; 95% CI, .3607 to 1.159;
P ¼ .1429) were observed in patients receiving grafts from
either A/A donors or B/x donors. In addition, no signiﬁcant
survival differences were observed among recipients from A/
A, A/B, or B/x donors (P¼ .5062). Divisions of A/A donors into
AA-1, AA-2, and AA-3 showed no differences in survival
(P ¼ .4902). In contrast, division of B/x donors into Bx1, Bx2,
and other B/x indicated that the donor KIR genotype Bx1 was
a risk factor for lower OS (HR, 8.667; 95% CI, 2.321 to 32.37;
P ¼ .0013) (Figure 4A) and RFS (HR, 9.207; 95% CI, 2.631 to
32.22; P¼ .0005) (Figure 4B) compared with other donor KIR
B/x genotypes.Figure 3. Donor-recipient KIR genotype mismatches and survival. Donor-recipient ge
(A) and AML patients (B), as well as RFS for all patients (C) and AML patients (D).Donor KIR B Haplotype of the Centromeric Motifs
Improved OS and RFS and Reduced Relapse for HLA-
identical Sibling HSCT
All donors with KIR haplotype A or B were divided into
3 groups: donor haplotype cB-tA/tB (n ¼ 34), cA-tB (n ¼ 61),
or cA-tA (n ¼ 124). Donors haplotype cB-tA/tB were associ-
ated with improved OS compared with cA-tB (96.6% versus
71.2%; HR, .2731; 95% CI, .091 to .822; P ¼ .021) or cA-tA
(96.6% versus 72.1%; HR, .3296; 95% CI, .132 to .823;
P ¼ .0174) (Figure 5A). RFS was also higher in donor haplo-
type cB-tA/tB group compared with cA-tB (96.9% versus
73.1%; HR, .2601; 95% CI, .092 to .730; P ¼ .0105) or cA-tA
(96.9% versus 52.4%; HR, .3038; 95% CI, .134 to .691;
P ¼ .0045) (Figure 5B). Furthermore, recipients from donors
with Cen-B (cB-tA/tB) had a relapse rate that was lower than
that in recipients from donors without Cen-B (cA-tB and cA-
tA) (2.9% versus 15.7%; P ¼ .047). No signiﬁcant differencesnotype mismatches had a beneﬁcial impact on overall survival for all patients
Figure 4. Donor KIR haplotype and survival. Donor KIR genotype Bx1 was a risk factor for overall survival (A) and relapse-free survival (B) compared with donor KIR
genotype with other B/x.
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IV aGVHD (P¼ .380), and cGVHD (P¼ .303). The ALL and CML
groups with donors having Cen-B were too small (n ¼ 7 and
n ¼ 5, respectively) for reliable analysis as a separate cate-
gory. The contribution of B haplotype genes in the telomeric
regions was also analyzed. However, the effect of Tel-B on OS,
RFS, aGVHD, cGVHD, NRM and relapse did not result in sig-
niﬁcant differences (data not shown). These results showed
that the B haplotype genes of the centromeric motifs had a
more beneﬁcial effect on improving the outcome of HSCT
than those of the telomeric motifs.Donor KIR and Recipient HLA-Cw Mismatches Model Had
a Protective Effect against aGVHD
All patients were assigned to 2 groups according to the
presence or absence of the C2 ligand in the recipients. Re-
cipients homozygous for the C1 ligand (C1/C1) were desig-
nated as “C1”; recipients that had the C2 ligand included
both C2/C2 homozygous and C1/C2 heterozygous individuals
and were designated as “C2.” OS (79.2% versus 70.4%; HR,
.6759; 95% CI, .3513 to 1.300; P ¼ .2406) and RFS (66.5%
versus 65.7%; HR, .5628; 95% CI, .2903 to 1.091; P ¼ .0887)
showed no signiﬁcant differences between patients with C1
and C2. Survival analysis indicated no signiﬁcant difference
for AML patients (73.1% versus 70.8%; HR, .7303; 95% CI,
.3320 to 1.606; P¼ .4345). However, aGVHDwas signiﬁcantly
lower in the C1 patients (23.2% versus 43.2%; P ¼ .002),
especially for the patients with AML (21.5% versus 49.0%;
P ¼ .001). No differences were found in NRM (P ¼ .370),
relapse (P ¼ .509), grade III to IV aGVHD (P ¼ .073), and
cGVHD (P ¼ .368). Very similar results were observed in AML
patients for NRM (P ¼ .538), relapse (P ¼ .419), grade III to IV
aGVHD (P ¼ .989), and cGVHD (P ¼ .188).
Assessment of patient HLA-B type showed that OS was
similar between Bw4-positive group (donor KIR3DL1þ andFigure 5. Donor KIR haplotype with Cen-B and survival. Donor KIR haplotype cB-tA/tB
compared with cA-tA and cA-tB.patient Bw4þ, or donor KIR3DL1- and patient Bw4þ/) and
Bw4-negative group (KIR3DL1þ and Bw4-) (77.3% versus
72.9%; HR, .8198; 95% CI: .4092 to 1.643; P ¼ .5752). A trend
toward improved RFS was observed in the Bw4-positive
group (72.5% versus 57.4%; HR, .5986; 95% CI, .3139 to
1.142; P ¼ .1193). No signiﬁcant differences were found in
NRM (P¼ .218), relapse (P¼ .584), aGVHD (P¼ .308), grade III
to IV aGVHD (P ¼ .856), and cGVHD (P ¼ .074). In the analysis
of HLA-A ligands, there were no signiﬁcant differences be-
tween the 2 groups in terms of OS (70.4% versus 78.6%; HR,
1.397; 95% CI, .7051 to 2.766; P ¼ .3381) and RFS (64.9%
versus 68.7%; HR, 1.318; 95% CI, .7005 to 2.478; P ¼ .3922)
according to the presence or absence of HLA-A3/-A11. No
signiﬁcant differences were found in NRM (P ¼ .986), relapse
(P ¼ .122), aGVHD (P ¼ .270), grade III to IV aGVHD (P ¼ .832),
and cGVHD (P ¼ .425).Multivariate Analysis
To further determine the effects of KIR on the outcome of
HSCT, a multivariate analysis was performed. This analysis
showed that donor KIR haplotype B of the centromeric mo-
tifs was an independent protective factor for OS (HR, .121;
95% CI, .016 to .933; P ¼ .043), RFS (HR, .086; 95% CI, .011 to
.662; P ¼ .018), and lower relapse (HR, .229; 95% CI, .062 to
.845; P ¼ .027). In contrast, expression of C1 ligands in pa-
tients was a protective factor against aGVHD (HR, .316; 95%
CI, .160 to .625; P ¼ .001), and advanced stage of the disease
at the time of transplantation was a risk factor for OS (HR,
2.591; 95% CI, 1.244 to 5.376; P ¼ .011) and RFS (HR, 2.105;
95% CI, 1.041 to 4.274; P ¼ .038) (Table 2). No effect was seen
for NRM and cGVHD (data not shown).DISCUSSION
The main results of this study indicated that KIR geno-
types and haplotypes play an important role in HLA-identicalwas associated with improved overall survival (A) and relapse-free survival (B)
Table 2
Multivariate Analysis of Survival, Acute Graft-versus-Host Disease, and Relapse
n OS RFS aGVHD Relapse
HR 95% CI P* HR 95% CI P* HR 95% CI Py HR 95% CI Py
Donor-recipient KIR compatibility (%)
Match 132 1 1 1 1
Mismatch 87 .545 .266-1.117 .097 .791 .419-1.495 .470 .903 .465-1.751 .762 .883 .386-2.020 .769
Donor KIR haplotype
A/A 124 1 1 1 1
B/x 95 .856 .431-1.699 .657 .855 .453-1.617 .631 .864 .481-1.783 .692 .765 .318-1.838 .549
Donor KIR haplotype
Without Cen-B 185 1 1 1 1
With Cen-B 34 .121 .016-.933 .043 .086 .011-.662 .018 .487 .161-1.468 .201 .229 .062-.845 .027
HLA-A alleles of recipients
A3/A11þ 63 1 1 1 1
A3/A11- 156 1.194 .609-2.339 .606 1.101 .590-2.056 .762 1.483 .748-2.941 .260 1.433 .636-3.228 .385
HLA-Bw alleles of recipients
Bw4þ 153 1 1 1 1
Bw4- 66 .833 .419-1.659 .604 .625 .335-1.167 .140 .778 .384-1.579 .488 .81 .350-1.874 .622
HLA-C alleles of recipients
C2 138 1 1 1 1
C1 81 .882 .451-1.724 .714 1.014 .539-1.907 .966 .316 .160-.625 .001 1.148 .491-2.682 .751
Disease status (%)
Standard risk 160 1 1 1 1
High risk 59 2.591 1.244-5.376 .011 2.105 1.041-4.274 .038 1.125 .490-2.584 .782 1.082 .387-3.030 .880
OS indicates overall survival; RFS, relapse-free survival; HR, hazard ratio; 95% CI, 95% conﬁdence interval.
* P values determined by Cox proportional hazards analysis.
y P values determined by multivariate proportional hazard regression analysis.
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mismatches improved survival and reduced grade III to IV
aGVHD, especially in AML patients. The donor KIR genotype
Bx1 was identiﬁed as a risk factor for survival. Because KIR B
haplotypes in the Bx1 genotype are in the telomeric part of
the KIR locus, we hypothesized that centromeric rather than
telomeric B motifs may confer a survival beneﬁt. Donor
centromeric and telomeric KIR haplotype analysis supported
this view, which showed that receiving cells from donors
with Cen-B was an independent protective factor for OS and
RFS.
Previous studies have examined the effect of donor and
recipient KIR genotypes on the outcome of allogeneic HSCT
[2,15,24,29]. The donor-recipient KIR gene mismatches
resulted in improved OS, RFS, and lower relapse in HLA-
haploidentical bone marrow transplantation [29]. Our re-
sults showed that 39.7% (87 of 219) of HLA-identical sibling
donor-recipient pairs was KIR genotype mismatched and
these mismatches showed improved OS and RFS with lower
rates of relapse and grade III to IV aGVHD, especially in AML/
MDS patients. Our HSCT results are consistent with previous
studies and further support that donor and recipient KIR
gene mismatches improve on the outcome of allogeneic
HSCT. In addition, donor-recipient KIR-mismatch group with
a donor genotype of KIR B/x had the best outcomewith lower
grade III to IV aGVHD and relapse rate. This result highlighted
the important role of donor KIR haplotype in the outcome of
HSCT from HLA-identical siblings.
The role of KIR genotype and haplotype in HLA-identical
sibling HSCT has been in controversial. Some studies re-
ported that KIR B haplotype had no beneﬁcial effects or even
that it was associated with a higher aGVHD [30,31]. A study
of HLA-matched sibling HSCT reported that transplantations
involving B/x donors and A/A recipients had the poorest
survival [2]. In contrast, our previous study indicated that a
donor KIR B haplotype improved transplantation outcomes
in HSCT with an unrelated donor [16]. As group B haplotypes
have more activating genes than haplotype A, transplantsfrom “B” haplotype donors are predicted to have more
prominent NK cell effects [17]. Another study has also shown
that when the donor expressed at least one KIR B haplotype
and the recipient was homozygous for the KIR A haplotype,
improved OS, RFS, and NRM were observed [15]. A study of
448 unrelated donor transplants for AML showed an
improved RFS if the donor had a “B” haplotype [17]. In this
study, we observed consistent result that KIR B haplotypes
showed a beneﬁcial role in HLA identical sibling HSCT.
Importantly, we found that donor presenting a KIR-Bx1 ge-
notype had the worst survival. Because KIR B haplotypes in
the Bx1 genotype are in the telomeric part of the KIR locus,
Cen-B motifs might play a more important role than telo-
meric B motifs. A recent study of 1086 AML patients suc-
cessfully distinguished the contribution of KIR for HSCT by
centromeric and telomeric motifs [32]. This study showed
that although both centromeric and telomeric B motifs
contributed to the relapse protection and improved survival,
Cen-B homozygosity had the strongest independent effect.
Concordantly, our research found that donors with Cen-B
had a beneﬁcial impact on OS and RFS with a lower relapse
rate than those without Cen-B. Multivariate analysis also
showed that a donor with KIR B haplotype of the centromeric
region was an independent protective factor for survival.
Although previous studies and our present study have sug-
gested the beneﬁcial role of Cen-B genes in relapse protec-
tion and improved survival in HLA-identical sibling HSCT,
molecular mechanisms remains largely unknown and func-
tional studies will be required to determine how Cen-B
donors protect against relapse.
Besides KIR genotype and haplotype, KIR receptor-ligand
mismatches also play an important role in predicting inhib-
itory KIR-driven donor NK alloreactivity. HLA-C ligands are
known as the major class I molecule important in NK cell-
mediated immune response after allogeneic HSCT. A previ-
ous report indicates that C1 patients have a better OS and
relapse control than C2 patients, particularly in myeloid
leukemia [33]. Moreover, a functional study has provided
H. Zhou et al. / Biol Blood Marrow Transplant 20 (2014) 98e105 105evidence that KIR2DL1 can discriminate between C1 and C2
groups, leading to differential lysis of C1 allele-expressing
leukemia blasts and inducing a graft-versus-leukemia effect
without causing GVHD [13]. Our study showed that patients
expressing C1 had a strongly protective effect against
aGVHD, especially for the patients with AML. Overall, our
ﬁndings support the view that the missing ligand model,
especially missing HLA-C ligands could induce NK cells
alloreactivity and thus improve the outcome of HLA-identical
sibling HSCT.
In conclusion, we have demonstrated that NK cell-
induced alloreactivity from donor to recipient depends on
KIR gene mismatches between the donor and recipient, on
donor KIR haplotype with centromeric B motifs, and a
missing ligand for HLA-C in HLA-identical sibling HSCT. This
KIR genotype and haplotype analysis has implications for
future clinical studies concerning selection of the most
suitable donor and prevention of transplantation related
complications for favorable clinical outcomes of HLA-
identical sibling HSCT.
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